BRCA1 and ovarian carcinoma: Clinical studies have shown that olaparib significantly prolongs the PFS in BRCA1/2 mutant ovarian cancer patients during both first-line maintenance therapy and platinum-sensitive relapse (PSR) maintenance treatment (Ledermann et al., 2016; Moore et al., 2018).